IRIDEX reports record Q3 revenue $14.6M, net loss narrows to $1.8M; maintains FY guidance

IRIDEX CORP

2022-Q3 EPS reported -$0.40 revenue$41,777,000

Total revenue $14.6M, +10% YoY, record Q3; net loss $1.8M ($0.11/share) vs $2.2M loss ($0.14) prior year.
Retina product revenue $8.8M (+13% YoY); Cyclo G6 revenue $3.5M (+10%).
FDA clearance of next-gen Pascal scanning laser system; first shipments in Q4.
FY revenue guidance maintained at $56-58M; probe units expected ~60,000 (down from 61-63k).
Cash $15.9M, used $2.1M in quarter including $0.5M inventory pre-orders.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported fiscal year 2022 results: revenue $56 million to $58 million. Guidance reaffirmed.

Period: fiscal year 2022
Revenue: $56 million to $58 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Iridex continues to expect total revenue for fiscal year 2022 to range from $56 million to $58 million, reflecting growth of 4% to 8% over fiscal year 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported the third quarter ended October 1, 2022 results: revenue $14.6 million, net income $1.8 million, EPS $0.11 per share.

Period: the third quarter ended October 1, 2022
Revenue: $14.6 million
Net income: $1.8 million
EPS: $0.11 per share
Result: reported results

Exact text from the filing

the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights • Total revenue of $14.6 million, a record third quarter revenue, and an increase of 10% over the prior year period • Gross Margin was 44.1% compared to 43.6% in the prior year period • Cyclo G6® product family

View on SEC.gov

Browse all earnings releases →

IRIDEX CORP filing history →

Source: SEC EDGAR

accession 0000950170-22-024501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.